Latest filings (excl ownership)
15-12B
Securities registration termination
30 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
8-K
Aytu BioScience Announces Close of Merger with Neos Therapeutics
22 Mar 21
425
Business combination disclosure
22 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
POS AM
Prospectus update (post-effective amendment)
19 Mar 21
POS AM
Prospectus update (post-effective amendment)
19 Mar 21
POS AM
Prospectus update (post-effective amendment)
19 Mar 21
POS AM
Prospectus update (post-effective amendment)
19 Mar 21
25-NSE
Exchange delisting
19 Mar 21
425
Business combination disclosure
12 Mar 21
425
Business combination disclosure
10 Mar 21
DEFA14A
Additional proxy soliciting materials
10 Feb 21
DEFM14A
Proxy related to merger
9 Feb 21
425
Business combination disclosure
8 Feb 21
8-K
Entry into a Material Definitive Agreement
8 Feb 21
425
Business combination disclosure
11 Jan 21
8-K
Corporate Presentation January 2021
11 Jan 21
425
Business combination disclosure
30 Dec 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Dec 20
425
Business combination disclosure
11 Dec 20
8-K
Entry into a Material Definitive Agreement
11 Dec 20
425
Business combination disclosure
10 Dec 20
8-K
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue1 Specialty Pharmaceutical Company
10 Dec 20
10-Q
2020 Q3
Quarterly report
9 Nov 20
8-K
Neos Therapeutics Reports Third Quarter 2020 Financial Results
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
8-K
Neos Therapeutics Reports Second Quarter 2020 Financial Results
10 Aug 20
8-K
Departure of Directors or Certain Officers
19 Jun 20
8-K
Entry into a Material Definitive Agreement
11 Jun 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jun 20
Latest ownership filings
4
John M Limongelli
19 Mar 21
4
James A. Jr. Robinson
19 Mar 21
4
Gerald W. McLaughlin
19 Mar 21
4
Beth Hecht
19 Mar 21
4
John P. Schmid
19 Mar 21
4
Bryant Fong
19 Mar 21
4
Linda M Szyper
19 Mar 21
4
GREGORY J ROBITAILLE
19 Mar 21
4
ALAN L HELLER
19 Mar 21
4
Richard I Eisenstadt
19 Mar 21
4
Gerald W. McLaughlin
16 Mar 21
4
John M Limongelli
16 Mar 21
4
Richard I Eisenstadt
16 Mar 21
SC 13G/A
SPHERA FUNDS MANAGEMENT LTD.
16 Feb 21
SC 13G/A
Stonepine Capital Management, LLC
12 Feb 21
SC 13G/A
Nantahala Capital Management, LLC
12 Feb 21
SC 13G/A
GOLDMAN SACHS & CO. LLC
12 Feb 21
4
Linda M Szyper
11 Jun 20
4
John P. Schmid
11 Jun 20
4
GREGORY J ROBITAILLE
11 Jun 20
4
James A. Jr. Robinson
11 Jun 20
4
ALAN L HELLER
11 Jun 20
4
Beth Hecht
11 Jun 20
4
Bryant Fong
11 Jun 20
4
Gerald W. McLaughlin
16 Mar 20
4
John M Limongelli
4 Mar 20
4
Gerald W. McLaughlin
4 Mar 20
4
Richard I Eisenstadt
4 Mar 20
SC 13G/A
Neos Therapeutics, Inc.
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G/A
Neos Therapeutics, Inc.
11 Feb 20
SC 13G
Beneficial ownership report
31 Jan 20
SC 13G/A
Neos Therapeutics, Inc.
10 Jul 19
SC 13G
Neos Therapeutics, Inc.
2 Jul 19
4
Linda M Szyper
17 Jun 19
4
John P. Schmid
17 Jun 19
4
GREGORY J ROBITAILLE
17 Jun 19
4
James A. Jr. Robinson
17 Jun 19
4
ALAN L HELLER
17 Jun 19